Recent insights into CD4+ T-cell specificity and function in type 1 diabetes

Expert Review of Clinical Immunology

Volumn 3, Issue 4, 2007, Pages 557-564

  Mannering, Stuart I ^a   Brodnicki, Thomas C ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CELL ANTIGEN; GLUCOSE 6 PHOSPHATASE; GLUTAMATE DECARBOXYLASE; HLA ANTIGEN; HLA ANTIGEN CLASS 2; INSULIN; PANCREAS ISLET CELL ANTIGEN; PROINSULIN; T LYMPHOCYTE ANTIGEN; TETRAMER; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL SPECIFICITY; DIABETOGENESIS; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 34447647103     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.4.557     Document Type: Review

References (86)

1. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N. Engl. J. Med. 331(21), 1428-1436 (1994).
2. Harrison LC. Risk assessment, prediction and prevention of Type 1 diabetes. Pediatr. Diabetes 2(2), 71-82 (2001).
3. Serreze DV. Leiter EH. Genes and cellular requirements for autoimmune diabetes susceptibility in nonobese diabetic mice. Curr. Dir. Autoimmun. 4, 31-67 (2001).
4. Shoda LK, Young DL, Ramanujan S et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23(2), 115-126 (2005).
5. Maier LM, Wicker LS. Genetic susceptibility to Type 1 diabetes. Curr. Opin. Immunol. 17(6), 601-608 (2005).
6. Papaccio G. Insulitis and islet microvasculature in Type 1 diabetes. Histol. Histopathol. 8(4), 751-759 (1993).
7. + T cells. J. Exp. Med. 166(4), 823-832 (1987).
8. + islet-specific T cell clone. Science 249(4975), 1433-1436 (1990).
9. Sefreze DV, Chapman HD, Varnum DS et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig μ null mice. J. Exp. Med. 184(5), 2049-2053 (1996).
10. Silveir PA, Grey ST. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of Type 1 diabetes. Trends Endocrinol. Metab. 17(4), 128-135 (2006).
11. Lampeter EF, McCann SR, Kolb H. Transfer of diabetes Type 1 by bone-marrow transplantation. Lancet 351(9102), 568-569 (1998).
12. Martin S, Wolf-Eichbaum D, Duinkerken G et al. Development of Type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 345(14), 1036-1040 (2001).
13. Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am. J. Hum. Genet. 59(5), 1134-1148 (1996).
14. Pugliese A, Eisenbarth GS. Human Type 1 diabetes mellitus: genetic susceptiblity and resistance. In: Type 1 Diabetes. Molecular, Cellular, and Clinical Immunology. Eisenbarth GS, Lafferty KJ (Eds.). Oxford University Press, NY, USA, and Oxford, UK 134-152 (1996).
15. Ridgway WM, Fathman CG. MHC structure and autoimmune T cell repertoire development. Curr. Opin. Immunol. 11(6), 638-642 (1999).
16. Sheehy MJ, Scharf SJ, Rowe JR et al. A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles. J. Clin. Invest. 83(3), 830-835 (1989).
17. Tomlinson IP, Bodmer WF, The HLA system and the analysis of multifactorial genetic disease. Trends Genet. 11 (12), 493-498. (1995).
18. Todd JA, Bell JI, McDevitt HO. HLA-DQ β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329(6140), 599-604 (1987).
19. Owerbach D, Gabbay KH. Localization of a Type I diabetes susceptibility locus to the variable tandem repeat region flanking the insulin gene. Diabetes 42(12), 1708-1714 (1993).
20. Vang T, Congia M, Macis MD et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37(12), 1317-1319 (2005).
21. Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423(6939), 506-511 (2003).
22. Morahan G, Huang D, Ymer SI et al. Linkage disequilibrium of a Type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat. Genet. 27(2), 218-221 (2001).
23. Vella A, Cooper JD, Lowe CE et al. Localization of a Type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76(5), 773-779 (2005).
24. Pugliese A, Zeller M, Fernandez A Jr et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for Type 1 diabetes. Nat. Genet. 15(3), 293-297 (1997).
25. Bennett ST, Lucassen AM, Gough SC et al. Susceptibility to human Type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat. Genet. 9(3), 284-292 (1995).
26. Vafiadis P, Bennett ST, Todd JA et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet. 15(3), 289-292 (1997).
27. Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in Type 1 diabetes and other autoimmune diseases. Semin. Immunol. 18(4), 207-213 (2006).
28. + regulatory T cells. Novartis Found. Symp. 252, 55-63; discussion 63-56, 106-114 (2003).
29. Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol. 28(1), 33-38 (2007).
30. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4(9), 665-674 (2004).
31. Haskins K. Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse. Adv. Immunol. 87, 123-162 (2005).
32. Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on Type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol. 148(1), 1-16 (2007).
33. Nakayama M, Abiru N, Moriyama H et al. Prime role for an insulin epitope in the development of Type 1 diabetes in NOD mice. Nature 435(7039), 220-223 (2005).
34. Krishnamurthy B, Dudek NL, McKenzie MD et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J. Clin. Invest. 116(12), 3258-3265 (2006).
35. Baker FJ, Lee M, Chien YH, Davis MM. Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice. Proc. Natl Acad. Sci. USA 99(14), 9374-9379 (2002).
36. Gelber C, Paborsky L, Singer S et al. Isolation of nonobese diabetic mouse T-cells that recognize novel autoantigens involved in the early events of diabetes. Diabetes 43(1), 33-39 (1994).
37. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononudear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J. Immunol. 157(12), 5668-5674 (1996).
38. Mannering SI, Purcell AW, Honeyman MC, McCluskey J, Harrison LC. Human T-cells recognise N-terminally Fmoc-modified peptide. Vaccine 21(25-26), 3638-3646 (2003).
39. Nagvekar N, Corlett L, Jacobson LW et al. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J. Immunol. 162(7), 4079-4087. (1999).
40. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol. 18(1), 92-97 (2006).
41. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat. Med. 6(3), 337-342. (2000).
42. Molberg O, McAdam SN, Korner R et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4(6), 713-717.(1998).
43. Girbal-Neuhauser E, Durieux JJ, Arnaud M et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of(pro)filaggrin by deimination of arginine residues. J. Immunol. 162(1), 585-594 (1999).
44. Kent SC, Chen Y, Bregoli L et al. Expanded T cells from pancreatic lymph nodes of Type 1 diabetic subjects recognize an insulin epitope. Nature 435(7039), 224-228 (2005).
45. Mannering SI, Harrison LC, Williamson NA et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med. 202(9), 1191-1197 (2005).
46. You S, Thieblemont N, Alyanakian MA, Bach JF, Chatenoud L. Transforming growth factor-β and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol. Rev. 212, 185-202 (2006).
47. Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 212, 217-237 (2006).
48. Suri-Payer E, Fritzsching B. Regulatory T cells in experimental autoimmune disease. Springer Semin. Immunopathol. 28(1), 3-16 (2006).
49. Tang Q, Henriksen KJ, Bi M et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199(11), 1455-1465 (2004).
50. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199(11), 1467-1477 (2004).
51. + regulatory T cells from nonobese diabetic mice. J. Immunol. 175(5), 3053-3059 (2005).
52. + regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204(1), 191-201 (2007).
53. French MB, Allison J, Cram DS et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 46(1), 34-39 (1997).
54. Steptoe RJ, Ritchie JM, Hat rison LC. Transfer of hematopoietic stem cells encoding autoantigen prevents autoinimune diabetes. J. Clin. Invest. 111(9), 1357-1363 (2003).
55. + regulatory T-cells in Type 1 diabetes. Diabetes 56(3), 604-612 (2007).
56. + T-cells from patients with Type 1 diabetes. Diabetes 54(1), 92-99 (2005).
57. + T-cell fraction. PLoS ONE 2, e146 (2007).
58. Tiittanen M, Huupponen JT, Knip M, Vaarala O. Insulin treatment in patients with Type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro. Diabetes 55(12), 3446-3454 (2006).
59. Tree TI, Duinkerken G, Willemen S, de Vries RR, Roep BO. HLA-DQ-regulated T-cell responses to islet cell autoantigens insulin and GAD65. Diabetes 53(7), 1692-1699 (2004).
60. Seyfert-Margolis V, Gisler TD, Asare AL et al. Analysis of T-cell assays to measure autoimmune responses in subjects with Type 1 diabetes: results of a blinded controlled study. Diabetes 55(9), 2588-2594 (2006).
61. Bingley PJ, Williams AJ, Gate EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care 22(11), 1796-1801 (1999).
62. Meierhoff G, Ott PA, Lehmann PV, Schloot NC. Cytokine detection by ELISPOT. relevance for immunological studies in Type 1 diabetes. Diabetes Metab. Res. Rev. 18(5), 367-380. (2002).
63. Schloot NC, Meierhoff G, Karlsson Faresjo M et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology ofdiabetes society T-cell workshop. J. Autoimmun. 21(4), 365-376 (2003).
64. Kotani R, Nagata M, Moriyama H et al. Detection of GAD65-reactive T-cells in Type 1 diabetes by immunoglobudin-free ELISPOT assays. Diabetes Care 25(8), 1390-1397 (2002).
65. Ott PA, Berner BR, Herzog BA et al. CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. J. Immunol. Methods 285(2), 223-235 (2004).
66. Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113 (3), 451-463 (2004).
67. Alleva DG, Crowe PD, Jin L et al. A disease-associated cellular immune response in Type 1 diabetics to an immunodominant epitope of insulin. J. Clin. Invest. 107(2), 173-180. (2001).
68. Ott PA, Herzog BA, Quast S et al. Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. Clin. Immunol. 115 (1), 102-114 (2005).
69. Ott PA, Dittrich MT, Herzog BA et al. T cells recognize multiple gad65 and proinsulin epitopes in human Type 1 diabetes, suggesting determinant spreading. J. Clin. Inimunol. 24(4),327-339 (2004).
70. Endl J, Rosinger S, Scliwarz B et al. Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in Type 1 diabetes. Diabetes 55(1), 50-60 (2006).
71. + subpopulation in new-onset disease. Clin. Exp. Immunol. 147(3), 472-482 (2007).
72. + T cells. J. Immunol. Methods 268(1), 71-81 (2002).
73. Mallone R, Nepom GT. MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clin. Immunol. 110(3), 232-242 (2004).
74. + T cells in human subjects. J. Immunol. 176(5), 2781-2789 (2006).
75. Reijonen H, Novak EJ, Kochik S et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in Type 1 diabetic patients and at-risk subjects. Diabetes 51(5), 1375-1382. (2002).
76. + T cells in healthy and Type 1 diabetic subjects. J. Autoimmun. 25 (4), 303-311 (2005).
77. + T-cells detected by MHC class II tetramers in peripheral blood of Type 1 diabetes patients and at-risk subjects. J. Autoimmun. 25 (3), 235-243 (2005).
78. Mallone R, Kochik SA, Laughlin EM et al. Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells. Diabetes 53(4), 971-977 (2004).
79. + T cells. Blood 106(8), 2798-2805 (2005).
80. Preda-Pais A, Stan AC, Casares S, Bona C, Brumeanu TD. Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes. J. Autoimmun. 25(1), 21-32 (2005).
81. Preda I, McEvoy RC, Lin M et al. Soluble, dimeric HLA DR4-peptide chimeras: an approach for detection and immunoregulation of human type- 1 diabetes. Eur. J. Immunol. 35(9), 2762-2775 (2005).
82. Kwok WW, Gebe JA, Liu A et al. Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol. 22(11), 583-588. (2001).
83. Dosch H, Cheung RK, Karges W, Pietropaolo M, Becker DJ. Persistent T cell anergy in human Type 1 diabetes. J. Immunol. 163(12), 6933-6940. (1999).
84. Mannering SI, Morris JS, Jensen KP et al. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J. Immunol. Methods 283(1-2), 173-183 (2003).
85. Mannering SI, Dromey JA, Morris JS, Thearle DJ, Jensen KP, Harrison LC. An efficient method for cloning human autoantigen-specific T cells. J. Immunol. Methods 298(1-2), 83-92 (2005).
86. Turcanu V, Maleki SJ, Lack G. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J. Clin. Invest. 111(7), 1065-1072 (2003).